Answers are grounded in this paper and cite their sources.
Selective Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) have revolutionized the treatment of breast cancer and have potential in other cancers, being manageable drugs yet with some bone marrow toxicity. Selective CDK9 inhibitors (CDK9i) never advanced into clinical use, partly due to side effects, including gastrointestinal toxicity, and a small window between activity and cytotoxicity, which results in a narrow therapeutic index (TI).
No takes yet. Share an insight, caveat, or question.
Forni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: